177O Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup

Autor:	K. Yonemori, K. Fujiwara, K. Hasegawa, M. Yunokawa, K. Ushijima, S. Suzuki, A. Shikama, S. Minobe, T. Usami, J-W. Kim, B-G. Kim, P-H. Wang, T-C. Chang, K. Yamamoto, S. Han, J. McKenzie, G. Barresi, T. Miura, V. Makker, Y.M. Kim
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1504-S1505
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d2597613ea2ead4ce9b57138a8e42ba6 https://doi.org/10.1016/j.annonc.2022.10.213 Zobrazit plný text záznamu